Precipio, Inc. (PRPO) Stock

Precipio, Inc. (PRPO) is a Technology stock trading at $28.99 (as of 2026-08-20), with a market capitalization of $51.90M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Precipio, Inc. provides diagnostic products, reagents, and services for blood cancer and other diagnostic testing in the United States. Its offerings include cell culture media (IV-Cell), genetic diagnostic panels (HemeScreen), specimen technology for molecular tests (ICE-COLD PCR), and antibody tests, with technology kits sold to biopharma customers and additional services for diagnostic testing providers.

Understand Precipio, Inc.: how it makes money

Precipio, Inc. provides healthcare diagnostic solutions, it runs diagnostic blood cancer testing services and sells proprietary ICE-COLD PCR technology kits to bio-pharma customers, and it also offers products including cell culture media (IV-Cell) and genetic diagnostic panels (HemeScreen).

Precipio’s profit model appears to be driven by whether it can turn its proprietary diagnostic platforms (services and ICE-COLD PCR kits) into actual revenue, because the data provided emphasizes annualized services capacity and pipeline revenue potential rather than current revenue.

Revenue by segment (latest quarter)
Products	$0.0B

Business quality (Weak): Revenue for the latest quarter is reported as 0.0B, and the available segment and operating items skew toward annualized capacity and pipeline potential, which makes near-term earnings power harder to verify.

Bull case

Proprietary diagnostics platform breadth: The company provides multiple diagnostic offerings, including IV-Cell (cell culture media), HemeScreen (genetic diagnostic panels), ICE-COLD PCR specimen technology, and diagnostic testing services for blood cancers.
Two monetization routes: It sells ICE-COLD-PCR technology kits to bio-pharma customers and also provides diagnostic pathology services, so revenue can come from both services and product sales.
Measurable commercialization workstreams: The operating KPIs provided include capacity, pipeline potential, and relationship and opportunity building metrics (for example, distributor representatives and qualified customer opportunities).

Bear case

Latest quarter revenue is 0.0B: In the latest reported quarter (2026-03-31), revenue is shown as 0.0B, which limits visibility into how quickly products and services are converting into sales.
Loss-making operating performance: Operating margin is -21.3%, indicating operating expenses exceeded gross profit in the latest quarter.
Dependence on pipeline conversion and scaling: Key operating items provided emphasize annualized services capacity and current annualized commercial pipeline revenue potential, which suggests future results depend on converting pipeline into recurring revenue and scaling production and services.

Valuation — source: SEC EDGAR (first-party)
Price	$28.99
Market Cap	$51.90M
Price / Book	3.52
Price / Sales	1.91
FCF Yield	1.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$24.05M
Net Margin	-1.5%
Revenue Growth (YoY)	24.2%
EPS Growth (YoY)	-340.0%
FCF Growth (YoY)	79.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.09 (distress)
Piotroski F-Score	7/9 (strong)

Valuation vs Sector & Industry
Sector P/E (Technology)	33.9
Industry P/E (Measuring & Control Equipment)	51.8

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($725550.00)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Measuring & Control Equipment
CEO	Ilan Danieli
Employees	54
Country	US
IPO Date	2017-06-30

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.